-+ 0.00%
-+ 0.00%
-+ 0.00%

BioVie Presents New Biomarker Data From ADDRESS-LC Trial Of Bezisterim In Long COVID; Analyses Suggest Single Efficacy Endpoint May Not Adequately Capture Clinically Meaningful Response To Therapeutic Intervention Across Biological Diversity Of Long Covid

Benzinga·11/09/2026 13:05:18
Listen to the news

New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes1 associated with different patient responses to bezisterim treatment.

Patients with a high-inflammatory endotype showed improvements in objective cognitive impairment, while those with a low-myeloid endotype experienced improvements in fatigue and post-exertional malaise.